Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same

被引:16
|
作者
Sahu, Vishal [1 ]
Nigam, Lokesh [2 ]
Agnihotri, Vertica [1 ]
Gupta, Abhishek [1 ]
Shekhar, Shashank [1 ]
Subbarao, Naidu [2 ]
Bhaskar, Suntan [3 ]
Dey, Sharmistha [1 ]
机构
[1] All India Inst Med Sci, Dept Biophys, Ansari Nagar, India
[2] Jawaharlal Nehru Univ, Sch Computat & Integrat Sci, New Delhi, India
[3] All India Inst Med Sci, Dept Radiat Oncol, Ansari Nagar, India
来源
CANCER RESEARCH AND TREATMENT | 2019年 / 51卷 / 01期
关键词
Head and neck squamous cell carcinoma; Surface plasmon resonance; p38; isoforms; Peptide inhibitor; Serum; Molecular docking; MAP KINASE; ACTIVATION; REVEALS; PROTEIN; HNSCC;
D O I
10.4143/crt.2018.105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The p38 mitogen-activated protein kinase (MAPKs) play a crucial role in the production of pro-inflammatory cytokines and over-expression of it increase cytokines which promote cancer. Among four isoforms, p38 alpha has been well studied in head and neck squamous cell carcinoma (HNSCC) and other cancers as a therapeutic target p38 delta has recently emerged as a potential disease-specific drug target. Elevated serum p38 alpha level in HNSCC was reported earlier from our lab. This study aims to estimate the levels of p38 MAPK-isoforms in the serum of HNSCC and design peptide inhibitor targeting the same. Materials and Methods Levels of p38 MAPK isoforms in the serum of HNSCC and healthy controls were quantified by surface plasmon resonance technology. The peptide inhibitor for p38 MAPK was designed by molecular modeling using Grid-based Ligand Docking with Energetics tools and compared with known specific inhibitors. Results We have observed highly elevated levels of all four isoforms of p38 MAPK in serum of HNSCC patients compared to the control group. Further, serum p38 alpha, p38 beta, and p38 delta levels were down regulated after therapy in follow-up patients, while p38 gamma showed no response to the therapy. Present study screened designed peptide WFYH as a specific inhibitor against p38 delta. The specific inhibitor of p38 delta was found to have no effect on p38 alpha due to great structural difference at ATP binding pocket. Conclusion In this study, first time estimated the levels of p38 MAPK isoforms in the serum of HNSCC. It can be concluded that p38 MAPK isoforms can be a diagnostic and prognostic marker for HNSCC and p38 delta as a therapeutic target.
引用
收藏
页码:313 / 325
页数:13
相关论文
共 50 条
  • [21] The Third Conformation of p38α MAP Kinase Observed in Phosphorylated p38α and in Solution
    Akella, Radha
    Min, Xiaoshan
    Wu, Qiong
    Gardner, Kevin H.
    Goldsmith, Elizabeth J.
    [J]. STRUCTURE, 2010, 18 (12) : 1571 - 1578
  • [22] Chemical genetics define the roles of p38α and p38β in acute and chronic inflammation
    O'Keefe, Stephen J.
    Mudgett, John S.
    Cupo, Susan
    Parsons, Janey N.
    Chartrain, Nicole A.
    Fitzgerald, Catherine
    Chen, Shiow-Ling
    Lowitz, Karen
    Rasa, Cordelia
    Visco, Denise
    Luell, Silvi
    Carballo-Jane, Ester
    Owens, Karen
    Zaller, Dennis M.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (48) : 34663 - 34671
  • [23] The three-dimensional structure of MAP kinase p38β: different features of the ATP-binding site in p38β compared with p38α
    Patel, Sangita B.
    Cameron, Patricia M.
    O'Keefe, Stephen J.
    Frantz-Wattley, Betsy
    Thompson, Jed
    O'Neill, Edward A.
    Tennis, Trevor
    Liu, Luping
    Becker, Joseph W.
    Scapin, Giovanna
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2009, 65 : 777 - 785
  • [24] 再谈P38闪电
    袁来
    [J]. 航空世界, 2003, (07) : 41 - 45
  • [25] The role of p38 in epilepsy
    Namiki, Kana
    Nakamura, Akira
    Furuya, Mitsuko
    Matsuo, Yuji
    Tokuhara, Naoki
    Sudo, Tatsuhiko
    Hama, Hiroshi
    Kuwaki, Tomoyuki
    Fukamizu, Akiyoshi
    Yano, Shingo
    Kimura, Sadao
    Kasuya, Yoshitoshi
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2007, 103 : 108P - 108P
  • [26] p38 Signalling Pathway
    Sanz-Ezquerro, Juan Jose
    Cuenda, Ana
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (03)
  • [27] Benzimidazolone p38 inhibitors
    Dombroski, MA
    Letavic, MA
    McClure, KF
    Barberia, JT
    Carty, TJ
    Cortina, SR
    Csiki, C
    Dipesa, AJ
    Elliott, NC
    Gabel, CA
    Jordan, CK
    Labasi, JM
    Martin, WH
    Peese, KM
    Stock, IA
    Svensson, L
    Sweeney, FJ
    Yu, CH
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (04) : 919 - 923
  • [28] p38 MAPK in MDS
    Ganan-Gomez, Irene
    Bohannan, Zachary S.
    Garcia-Manero, Guillermo
    [J]. AGING-US, 2015, 7 (06): : 346 - 347
  • [29] P38 kinase inhibitors
    Lloyd, AW
    [J]. DRUG DISCOVERY TODAY, 2000, 5 (12) : 570 - 571
  • [30] Inhibitors of p38 kinase
    Hanson, GJ
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (07) : 729 - 733